Yung-Hsi Wen
Interventional Cardiology · Glendale, CANPI 1366585309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,264 and has fallen 98.7% since, to $17 in 2022. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 183 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$582
- Novartis$525
- Johnson & Johnson$376
- Amarin Pharma, Inc.$246
- AstraZeneca$239
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$232
- plus $905 from 13 others
What the payments were for
- Food & beverage$3,08099%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 42 | $582 |
| Novartis | 32 | $525 |
| Johnson & Johnson | 14 | $376 |
| Amarin Pharma, Inc. | 12 | $246 |
| AstraZeneca(2 entities) | 13 | $239 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $232 |
| Esperion Therapeutics, Inc. | 22 | $174 |
| E.r. Squibb & Sons, L.L.C. | 11 | $161 |
| Boehringer Ingelheim | 5 | $123 |
| Medtronic | 1 | $100 |
| Pfizer | 4 | $78 |
| Merck | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Tactile Systems Technology Inc | 2 | $31 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
| Novo Nordisk | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$100
How this compares
$3,104 in reported general payments places this provider in the 25th percentile of 585 interventional cardiology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 11 | $163 |
| Ezetimibe | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Glendale
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.